CSPC Pharmaceutical Group Grants Exclusive License of Cancer Inhibitor to BeiGene Switzerland

MT Newswires04:48 ET

Express News | JPMorgan Chase & Co's Long Position in Shares of Beigene Increases to 10.94% on Dec 9 From 9.92% - HKEX

Reuters04:22 ET

Reported Earlier, BeiGene Secures Global Licensing Agreement For Novel MAT2A Inhibitor SYH2039 To Target MTAP-Deleted Solid Tumors

Benzinga02:25 ET

CSPC PHARMA and BEIGENE have entered into an exclusive licensing agreement for SYH2039.

CSPC PHARMA (01093) announced that the group has entered into an exclusive licensing agreement with BeiGene Switzerland GmbH (BEIGENE) for the group's novel methionine adenosyltransferase 2A (MAT2A) inhibitor (SYH2039), as well as for any Pharmaceuticals composed of or containing this compound for development, manufacturing, and commercialization on a Global scale. Under the agreement, and in accordance with its terms and conditions, the group agrees to grant BEIGENE exclusive rights for the Global development, manufacturing, and commercialization of that compound and product. The group will receive a total of 1.50.

Sina Hong Kong Stock.20:10 ET

CSPC Pharmaceutical Partners With BeiGene on Innovative Cancer Drug

TipRanks19:38 ET

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor

Businesswire19:30 ET